Crystalline forms of janus kinase inhibitor

The development of crystalline forms of Compound A addresses the need for stable solid state JAK inhibitors, enabling effective pharmaceutical compositions for treating autoimmune and inflammatory diseases.

JP2024161449APending Publication Date: 2024-11-19JAPAN TOBACCO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024134769
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-21
Filing Date
2024-08-13
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

There is a need for solid state forms of Janus kinase (JAK) inhibitors, such as Compound A, that possess effective properties like stability to heat and moisture, and facilitate the preparation of solid dosage forms for pharmaceutical use.

Method used

The development of crystalline forms of Compound A, specifically alpha, beta, and gamma crystals, which exhibit unique XRPD patterns, DSC thermograms, and 13C NMR spectra, allowing for the formulation of stable pharmaceutical compositions.

Benefits of technology

The crystalline forms of Compound A provide enhanced stability and facilitate the preparation of pharmaceutical compositions suitable for various administration routes, effectively inhibiting JAK kinases and treating related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161449000039
    Figure 2024161449000039
  • Figure 2024161449000040
    Figure 2024161449000040
  • Figure 2024161449000041
    Figure 2024161449000041
Patent Text Reader

Abstract

To provide crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions thereof, methods of their preparation, methods of use thereof, and methods of quantitation.SOLUTION: The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions thereof, methods of their preparation, methods of use thereof, and methods of quantitation.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) and compositions thereof, methods for their preparation, use and quantification. [Background technology]

[0002] Janus kinase (JAK) inhibitors are currently of interest in the treatment of various diseases, including autoimmune diseases, inflammatory diseases, and cancer. To date, two JAK inhibitors have been approved by the US Food and Drug Administration (FDA). Ruxolitinib has been approved for the treatment of primary myelofibrosis and polycythemia vera (PV), and tofacitinib has been approved for the treatment of rheumatoid arthritis. Other JAK inhibitors can be found in the literature. The compound 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) (structure below) is an example of a spirocyclic JAK inhibitor reported in US Patent Publication No. 2011 / 0136778 and International Application No. PCT / JP2016 / 070046. [ka]

[0003] Drug compounds, such as Compound A, are typically combined with other pharma- ceutical acceptable ingredients to form a composition suitable for administration to a patient. Solid formulations often require that drug compounds have effective solid state properties, such as heat and humidity stability, ease of handling, and other properties that facilitate the preparation of solid dosage forms. Thus, there is a continuing need for solid forms of existing drug molecules. The crystalline form of Compound A described herein is directed to this purpose. Summary of the Invention

[0004] The present invention is particularly directed to crystalline forms β and γ of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A). The present invention is further directed to compositions comprising alpha crystals in combination with beta crystals or gamma crystals or both. The present invention is further directed to pharmaceutical compositions comprising one or more of the crystalline forms or compositions of the present invention. The present invention is further directed to methods of preparing the crystalline forms of the present invention. The present invention is further directed to a method for quantifying the crystalline forms of the present invention. The present invention is further directed to a method of inhibiting Janus kinase comprising contacting a Janus kinase with a crystalline form of the present invention. The present invention is further directed to a method of treating or preventing a disease in a patient comprising administering to the patient a therapeutically effective amount of a crystalline form or composition of the invention. The present invention is further directed to a crystalline form or composition of the invention for use in prophylaxis or therapy. The present invention is further directed to the use of a crystalline form or composition of the invention in the manufacture of a medicament for prophylactic or therapeutic use. [Brief description of the drawings]

[0005] [Figure 1] FIG. 1 shows an XRPD pattern consistent with the α crystal. [Diagram 2] FIG. 2 shows an XRPD pattern consistent with the β crystal. [Diagram 3] FIG. 3 shows an XRPD pattern consistent with gamma crystals. [Figure 4] FIG. 4 shows a DSC thermogram consistent with α crystals. [Diagram 5] FIG. 5 shows a DSC thermogram consistent with the β crystal. [Figure 6] FIG. 6 shows a DSC thermogram consistent with gamma crystals. [Figure 7]FIG. 7 shows TG-DTA data consistent with alpha crystals. [Figure 8] FIG. 8 shows TG-DTA data consistent with the β crystal. [Figure 9] FIG. 9 shows TG-DTA data consistent with gamma crystals. [Figure 10] FIG. 10 shows solid state 13C NMR data consistent with the α crystal. [Figure 11] FIG. 11 shows solid state 13C NMR data consistent with the β crystal. [Figure 12] FIG. 12 shows solid state 13C NMR data consistent with the gamma crystal. [Figure 13] FIG. 13 shows an overlay of XRPD patterns obtained from standard samples of Compound A containing 0, 2, 5 and 10% β crystals (see Example 4). [Figure 14] FIG. 14 shows an overlay of XRPD patterns obtained from authentic samples of Compound A containing 0, 1, 2, 5 and 10% gamma crystals (see Example 4). [Figure 15] FIG. 15 shows, from the bottom, XRPD patterns of an α crystal of compound A used in Example 6, a β crystal of compound A used, a mixture of α crystal and β crystal of compound A in a weight ratio of 1:1 before stirring, and the crystal obtained after stirring. [Figure 16] FIG. 16 shows, from the bottom, the XRPD patterns of the α crystal of compound A used in Example 7, the γ crystal of compound A used, a 1:1 weight ratio mixture of the α crystal and the γ crystal of compound A before stirring, and the crystal obtained after stirring. [Figure 17] FIG. 17 shows, from the bottom, XRPD patterns of the γ crystals of compound A used in Example 8, the β crystals of compound A used, a 1:1 weight ratio mixture of β crystals and γ crystals of compound A before stirring, crystals obtained from formamide, crystals obtained from N,N-dimethylformamide, and crystals obtained from dimethyl sulfoxide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0006] The present invention provides, inter alia, crystalline forms of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, which are inhibitors of Janus kinases (JAKs) and are useful in treating a variety of diseases associated with Janus kinase upregulation or overexpression. In some embodiments, the crystalline forms of the present invention inhibit JAK3. In some embodiments, the crystalline forms of the present invention inhibit JAK2.

[0007] The present invention is as follows in one aspect. [Item 1] The β-form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile.

[0008] [Item 2] The crystalline form according to item 1, having a powder X-ray diffraction pattern including a characteristic peak at about 11.8 in 2θ (°).

[0009] [Item 3] The crystalline form according to item 1, having a powder X-ray diffraction pattern including two or more characteristic peaks selected from about 10.5, about 11.8, about 19.3 and about 22.0 at 2θ (°).

[0010] [Item 4] The crystalline form according to item 1, having a powder X-ray diffraction pattern including three or more characteristic peaks selected from about 7.8, about 10.5, about 11.8, about 13.4, about 13.9, about 17.8, about 19.3, about 22.0, about 23.6 and about 28.0 at 2θ (°).

[0011] [Item 5] The crystalline form according to any one of Items 1 to 4, having a DSC thermogram characterized by an endothermic peak at about 186°C.

[0012] [Item 6] A solid characterized by at least one peak at about 165.1 ppm. 13 6. The crystalline form according to any one of items 1 to 5, having a C NMR spectrum.

[0013] [Item 7] A solid characterized by at least five peaks selected from about 16.5, about 25.8, about 26.5, about 33.1, about 34.8, about 36.7, about 38.8, about 48.2, about 53.4, about 77.7, about 79.5, about 101.2, about 102.6, about 117.5, about 120.6, about 151.1, about 154.3 and about 165.1 ppm. 13 6. The crystalline form according to any one of items 1 to 5, having a C NMR spectrum.

[0014] [Term 8] Unit cell parameters: [Table 1] 8. The crystalline form according to any one of items 1 to 7, having a space group P1 represented by:

[0015] [Item 9] The crystalline form of any one of items 1 to 8, having a purity of at least about 50%.

[0016] [Item 10] The crystalline form of any one of items 1 to 8, having a purity of at least about 75%.

[0017] [Item 11] The crystalline form of any one of items 1 to 8, having a purity of at least about 85%.

[0018] [Item 12] The crystalline form of any one of items 1 to 8, having a purity of at least about 90%.

[0019] [Item 13] The crystalline form of any one of items 1 to 8, having a purity of at least about 95%.

[0020] [Item 14] A crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, which is a gamma crystal.

[0021] [Item 15] The crystalline form according to Item 14, having a powder X-ray diffraction pattern including a characteristic peak at about 16.5 in 2θ (°).

[0022] [Item 16] The crystalline form according to Item 14, having a powder X-ray diffraction pattern including two or more characteristic peaks selected from about 16.5, about 17.7, about 21.4, about 21.8 and about 23.1 at 2θ (°).

[0023] [Item 17] The crystalline form according to Item 14, having a powder X-ray diffraction pattern including three or more characteristic peaks selected from about 7.7, about 10.6, about 13.3, about 13.9, about 15.5, about 16.5, about 17.7, about 17.9, about 19.0, about 21.4, about 21.8, about 23.1, about 23.7 and about 28.1 at 2θ (°).

[0024] [Item 18] The crystalline form according to any one of Items 14 to 17, having a DSC thermogram characterized by an endothermic peak at about 196°C.

[0025] [Item 19] A solid characterized by at least one peak at about 162.9 ppm. 13 19. The crystalline form according to any one of items 14 to 18, having a C NMR spectrum.

[0026] [Item 20] A solid characterized by at least five peaks selected from about 16.9, about 26.5, about 32.9, about 36.4, about 48.1, about 53.7, about 78.6, about 102.6, about 116.4, about 117.9, about 121.5, about 151.8, about 154.6 and about 162.9 ppm. 13 20. The crystalline form according to any one of items 14 to 19, having a C NMR spectrum.

[0027] [Term 21] Unit cell parameters: [Table 2] 21. The crystalline form according to any one of items 14 to 20, having a space group P21 represented by:

[0028] [Item 22] The crystalline form of any one of items 14 to 21, having a purity of at least about 50%.

[0029] [Item 23] The crystalline form of any one of items 14 to 21, having a purity of at least about 75%.

[0030] [Item 24] The crystalline form of any one of items 14 to 21, having a purity of at least about 85%.

[0031] [Item 25] The crystalline form of any one of items 14 to 21, having a purity of at least about 90%.

[0032] [Item 26] The crystalline form of any one of items 14 to 21, having a purity of at least about 95%.

[0033] [Item 27] ​​A method for preparing the crystalline form of any one of items 1 to 13, comprising crystallizing 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile from a solvent.

[0034] [Item 28] The method according to Item 27, wherein the solvent comprises 1-butanol and acetonitrile.

[0035] [Item 29] The method according to Item 28, wherein the ratio of 1-butanol to acetonitrile is about 1:3 (v / v).

[0036] [Item 30] Crystalline form β prepared by the method according to any one of items 27 to 29.

[0037] [Item 31] A method for preparing the crystalline form according to any one of Items 14 to 26, comprising converting α-crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile to γ-crystals.

[0038] [Item 32] Item 32 comprises stirring α crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile in dimethylformamide (DMF). The method according to Item 31.

[0039] [Item 33] The method according to Item 31, comprising stirring α-crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile in formamide.

[0040] [Item 34] Crystalline form γ prepared by the method according to any one of items 31 to 33.

[0041] [Item 35] A composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, including α crystals and β crystals.

[0042] [Item 36] The composition according to item 35, which consists essentially of α crystals and β crystals.

[0043] [Item 37] The composition described in Item 35 or 36, wherein the β crystals are present in an amount of about 1 to about 50% w / w relative to the α crystals.

[0044] [Item 38] The composition described in Item 35 or 36, wherein the β crystals are present in an amount of about 1 to about 20% w / w relative to the α crystals.

[0045] [Item 39] The composition described in Item 35 or 36, wherein the β crystals are present in an amount of about 1 to about 10% w / w relative to the α crystals.

[0046] [Item 40] The composition described in Item 35 or 36, wherein the β crystals are present in an amount of about 1 to about 5% w / w relative to the α crystals.

[0047] [Item 41] The composition according to any one of items 35 to 40, further comprising gamma crystals.

[0048] [Item 42] A composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, including β-crystals and γ-crystals.

[0049] [Item 43] The composition according to item 42, which consists essentially of β crystals and γ crystals.

[0050] [Item 44] The composition described in Item 42 or 43, wherein the gamma crystals are present in an amount of about 1 to about 50% w / w relative to the beta crystals.

[0051] [Item 45] The composition described in Item 42 or 43, wherein the gamma crystals are present in an amount of about 1 to about 20% w / w relative to the beta crystals.

[0052] [Item 46] The composition described in Item 42 or 43, wherein the gamma crystals are present in an amount of about 1 to about 10% w / w relative to the beta crystals.

[0053] [Item 47] The composition described in Item 42 or 43, wherein the gamma crystals are present in an amount of about 1 to about 5% w / w relative to the beta crystals.

[0054] [Item 48] The composition according to any one of items 42 to 47, further comprising α crystals.

[0055] [Item 49] A pharmaceutical composition comprising the crystalline form or composition according to any one of items 1 to 48 and a pharma- ceutically acceptable carrier.

[0056] [Item 50] The pharmaceutical composition according to Item 49, further comprising a second therapeutic agent.

[0057] [Item 51] A pharmaceutical composition according to Item 49 or 50, suitable for oral, parenteral, pulmonary, partial or local administration.

[0058] [Item 52] The pharmaceutical composition according to Item 49 or 50, which is suitable for topical administration.

[0059] [Item 53] The pharmaceutical composition according to Item 49 or 50, which is in the form of a tablet, capsule, pill, powder or ointment.

[0060] [Item 54] The pharmaceutical composition of item 49 or 50, which is in the form of a powder suitable for reconstitution into a liquid for IV, IM or SC administration.

[0061] [Item 55] The pharmaceutical composition according to item 49 or 50, which comprises white petrolatum, solid paraffin, squalene or a mixture thereof.

[0062] [Item 56] A method for inhibiting Janus kinase, comprising contacting Janus kinase with a crystal form or composition described in any one of Items 1 to 55.

[0063] [Item 57] The method according to Item 56, wherein the Janus kinase is Janus kinase 3 (JAK3).

[0064] [Item 58] The method according to Item 56, wherein the Janus kinase is Janus kinase 2 (JAK2).

[0065] [Item 59] A method for treating or preventing a disease selected from organ transplant rejection, post-transplant graft-versus-host reaction, autoimmune diseases, allergic diseases, and chronic myeloproliferative disorders, comprising administering a therapeutically effective amount of a crystalline form or composition described in any one of Items 1 to 55 to a mammal.

[0066] [Item 60] A method for treating or preventing rheumatoid arthritis, psoriasis, alopecia areata, dry eye, atopic dermatitis, eczema, or hand eczema, comprising administering a therapeutically effective amount of a crystalline form or composition described in any one of Items 1 to 55 to a mammal.

[0067] [Item 61] A crystalline form or composition according to any one of items 1 to 55 for use as an active pharmaceutical ingredient.

[0068] [Item 62] The crystalline form or composition according to any one of Items 1 to 55 for use in the treatment or prevention of organ transplant rejection, post-transplant graft-versus-host reaction, autoimmune disease, allergic disease, or chronic myeloproliferative disorder.

[0069] [Item 63] The crystalline form according to any one of Items 1 to 55 for use in the treatment or prevention of rheumatoid arthritis, psoriasis, alopecia areata, dry eye, atopic dermatitis, eczema or hand eczema.

[0070] [Item 64] A method for measuring the amount of β crystals present in a preparation of α crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, comprising measuring the peak area of ​​an XRPD peak characteristic of β crystals and comparing the peak area with a standard.

[0071] [Item 65] The method according to Item 64, wherein a peak characteristic of β crystals is observed at about 10.6° 2θ.

[0072] [Item 66] A method for measuring the amount of gamma crystals present in a preparation of alpha crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, comprising measuring the peak area of ​​an XRPD peak characteristic of gamma crystals and comparing the peak area with a standard.

[0073] [Item 67] The method according to Item 66, in which a peak characteristic of gamma crystals is observed at about 16.6° 2θ.

[0074] As used herein, "crystal form" refers to a particular lattice arrangement of a crystalline substance. Different crystal forms of the same substance typically have different crystal lattices (e.g., unit cells) and different physical properties resulting from the different crystal lattices, and in some cases different water or solvent content. Different crystal lattices can be identified by solid-state characterization methods such as X-ray powder diffraction (XRPD). Other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), and solid-state NMR can further aid in identifying crystal forms and determining stability and solvent / water content.

[0075] Different crystalline forms of a particular substance can include both anhydrous and solvate / hydrate forms of the substance, each of which is distinguished from the other by a different XRPD pattern and therefore exhibits a different crystal lattice. In some cases, a single crystalline form (e.g., identified by a unique XRPD pattern) can have a variety of water or solvent contents, but the lattice remains substantially unchanged (as does the XRPD pattern) despite the varying composition of water and / or solvent.

[0076] XRPD patterns of reflections (peaks) are typically considered as fingerprints of a particular crystalline form. It is well known that the relative intensities of XRPD peaks can vary, among other things, depending on the sample preparation method, crystal size distribution, sample mounting procedure, and the particular instrument used. In some cases, new peaks may be observed or existing peaks may disappear, depending on the type of instrument or settings (e.g., whether or not a Ni filter is used). Furthermore, instrumental variations and other factors may affect the 2θ values. Thus, the peak identifications as described herein may vary by ±0.2°, ±0.1°, or ±0.04° (2θ), and the term "substantially" as used herein in the context of XRPD is meant to encompass such variations.

[0077] Similarly, temperature readings for DSC, TGA or other thermal experiments may vary by about ±3° C. depending on the equipment, particular settings, sample preparation, etc. Thus, temperature values ​​as described herein may vary by ±3° C., and it is understood that crystalline forms described herein having DSC thermograms or other thermograms "substantially" as shown in any of the drawings accommodate such variations.

[0078] In addition, the chemical shift 13 C NMR spectra can vary by ±0.2 ppm, and the term "substantially" as used in the context of NMR data herein is meant to encompass this variation.

[0079] β Akira The present invention provides a crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) which is the β-form. The crystalline form corresponding to the β-form is believed to be anhydrous as e.g. revealed by DSC and TG-DTA (see Example 2). In some embodiments, the β-form exhibits an X-ray powder diffraction pattern including a characteristic peak at about 11.8 in 2θ (°). In further embodiments, the β-form exhibits an X-ray powder diffraction pattern including two or more characteristic peaks selected from about 10.5, about 11.8, about 19.3 and about 22.0 in 2θ (°). In a further embodiment, the β crystal exhibits a powder X-ray diffraction pattern comprising three or more characteristic peaks selected from about 7.8, about 10.5, about 11.8, about 13.4, about 13.9, about 17.8, about 19.3, about 22.0, about 23.6 and about 28.0 at 2θ (°). In a further embodiment, the β crystal exhibits a powder X-ray diffraction pattern comprising three or more characteristic peaks selected from any of the peaks listed in Table 2-1 at 2θ (°) (see Example 2). In a further embodiment, the β crystal exhibits an XRPD pattern substantially as shown in FIG. 2.

[0080] In some embodiments, the β crystal exhibits a DSC thermogram characterized by an endothermic peak at about 186° C. In some embodiments, the β crystal exhibits a DSC thermogram characterized by an extrapolated onset temperature at about 185° C. In further embodiments, the β crystal exhibits a DSC thermogram substantially as shown in FIG.

[0081] In some embodiments, the β-form is characterized by at least one peak at about 165.1 ppm. 13 In a further embodiment, the β-crystal is characterized by at least five peaks selected from about 16.5, about 25.8, about 26.5, about 33.1, about 34.8, about 36.7, about 38.8, about 48.2, about 53.4, about 77.7, about 79.5, about 101.2, about 102.6, about 117.5, about 120.6, about 151.1, about 154.3, and about 165.1 ppm. 13 11 shows the C NMR spectrum. In a further embodiment, the β crystal is substantially as shown in FIG. 13 The C NMR spectrum is shown.

[0082] In some embodiments, the β crystal has unit cell parameters as determined by single crystal X-ray diffraction: [Table 3] (See Example 5)

[0083] The β-form may have a purity of at least about 50%, at least about 75%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, the β-form is substantially pure.

[0084] The β-form may be prepared by crystallizing 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (compound A) from a solvent. For example, compound A (e.g., as α-form) may be mixed with a solvent to form a solution or slurry from which β-form crystals can be obtained. In some embodiments, the solvent includes a nitrile such as acetonitrile or a mixture of 1-butanol and acetonitrile. In some embodiments, the solvent includes about 1-butanol and acetonitrile (v / v), respectively. In some embodiments, compound A may be mixed with a solvent and heated to a temperature of about 30 to about 50° C. In some embodiments, the mixture may be heated to about 35 to about 45° C., or to about 40° C. After heating, the mixture may be cooled to about room temperature (e.g., about 23° C.) to obtain a β-form crystalline product.

[0085] The present invention further provides β crystals prepared by any one of the above methods.

[0086] Gamma crystal The present invention also provides a crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) that is a gamma crystal. The crystalline form corresponding to the gamma crystal is believed to be anhydrous, as revealed, for example, by DSC and TG-DTA (see Example 3). In some embodiments, the gamma crystal exhibits an X-ray powder diffraction pattern including a characteristic peak at about 16.5 in 2θ (°). In further embodiments, the gamma crystal exhibits an X-ray powder diffraction pattern including two or more characteristic peaks selected from about 16.5, about 17.7, about 21.4, about 21.8, and about 23.1 in 2θ (°). In a further embodiment, the gamma crystal exhibits an X-ray powder diffraction pattern comprising three or more characteristic peaks selected from about 7.7, about 10.6, about 13.3, about 13.9, about 15.2, about 16.5, about 17.7, about 17.9, about 19.0, about 21.4, about 21.8, about 23.1, about 23.7 and about 28.1 at 2θ (°). In a further embodiment, the gamma crystal exhibits an X-ray powder diffraction pattern comprising three or more characteristic peaks selected from any of the peaks listed in Table 3-1 at 2θ (°) (see Example 3). In a further embodiment, the gamma crystal exhibits an XRPD pattern substantially as shown in FIG. 3.

[0087] In some embodiments, the gamma crystal exhibits a DSC thermogram characterized by an endothermic peak at about 196° C. In some embodiments, the gamma crystal exhibits a DSC thermogram characterized by an extrapolated onset temperature at about 196° C. In further embodiments, the gamma crystal exhibits a DSC thermogram substantially as shown in FIG.

[0088] In some embodiments, the gamma crystal is characterized by at least one peak at about 162.9 ppm. 13In a further embodiment, the gamma crystal is characterized by at least five peaks selected from about 16.9, about 26.5, about 32.9, about 36.4, about 48.1, about 53.7, about 78.6, about 102.6, about 116.4, about 117.9, about 121.5, about 151.8, about 154.6, and about 162.9 ppm. 13 11 shows the C NMR spectrum. In a further embodiment, the γ crystal is substantially as shown in FIG. 13 The C NMR spectrum is shown.

[0089] In some embodiments, the gamma crystal has unit cell parameters as determined by single crystal X-ray diffraction: [Table 4] (See Example 5)

[0090] The gamma crystals can have a purity of at least about 50%, at least about 75%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, the gamma crystals are substantially pure.

[0091] The gamma crystal can be prepared by converting the alpha crystal of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile to the gamma crystal. The conversion can be carried out, for example, by stirring the alpha crystal in dimethylformamide (DMF). The stirring can be carried out, for example, at room temperature. Alternatively, the gamma crystal can be prepared by mixing compound A with formamide and adding a seed crystal of the gamma crystal. The preparation can be carried out at room temperature, appropriately under an inert atmosphere such as nitrogen.

[0092] The present invention further provides γ crystals prepared by any of the above methods.

[0093] composition In addition to the β and γ crystals, Compound A can be prepared and obtained as anhydrous α crystal, which is described in Example 1. Thus, the present invention provides a mixture of two or more of the α, β and γ crystals of Compound A.

[0094] In some embodiments, the present invention provides a composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) comprising both α and β crystals. In some embodiments, the β crystals are present in an amount of about 1 to about 50% w / w relative to the α crystals. In further embodiments, the β crystals are present in an amount of about 1 to about 20% w / w relative to the α crystals. In further embodiments, the β crystals are present in an amount of about 1 to about 10% w / w relative to the α crystals. In further embodiments, the β crystals are present in an amount of about 1 to about 5% w / w relative to the α crystals. In some embodiments, the composition comprises α and β crystals and is substantially free of other crystalline forms of Compound A. In further embodiments, the composition comprising α and β crystals further comprises γ crystals. In some embodiments, the composition consists essentially of α and β crystals.

[0095] The present invention further provides a composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) comprising both β and γ crystals. In some embodiments, the γ crystals are present in an amount of about 1 to about 50% w / w relative to the β crystals. In further embodiments, the γ crystals are present in an amount of about 1 to about 20% w / w relative to the β crystals. In further embodiments, the γ crystals are present in an amount of about 1 to about 10% w / w relative to the β crystals. In further embodiments, the γ crystals are present in an amount of about 1 to about 5% w / w relative to the β crystals. In some embodiments, the composition comprises β and γ crystals and is substantially free of other crystalline forms of Compound A. In further embodiments, the composition comprising β and γ crystals further comprises α crystals. In some embodiments, the composition consists essentially of β and γ crystals.

[0096] The present invention further provides compositions comprising β or γ crystals and one or more other substances, in some embodiments, the compositions comprise at least about 50% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight of β or γ crystals.

[0097] Analysis method The present invention provides a method for measuring the amount of β crystals present in a preparation of α crystals, comprising measuring the peak area of ​​an XRPD peak characteristic of β crystals and comparing the peak area to a standard. In some embodiments, the peak characteristic of β crystals is at about 10.6° 2θ. The standard can be a calibration curve calculated from the peak area of ​​a known amount of β crystals in α crystals. Similarly, the present invention provides a method for measuring the amount of γ crystals present in a preparation of α crystals, comprising measuring the peak area of ​​an XRPD peak characteristic of γ crystals and comparing the peak area to a standard. In some embodiments, the peak characteristic of γ crystals is at about 16.6° 2θ. The standard can be a calibration curve calculated from the peak area of ​​a known amount of γ crystals in α crystals.

[0098] Pharmaceutical Compositions and Uses The crystalline forms of the present invention may be prepared as pharmaceutical compositions comprising the crystalline forms of the present invention or the compositions of the present invention together with at least one pharma- ceutical acceptable carrier (or excipient). In some embodiments, the pharmaceutical compositions are suitable for oral, parenteral, pulmonary, local or topical administration. In some embodiments, the pharmaceutical compositions are in the form of oral preparations such as tablets, capsules, granules, powders, lozenges, syrups, emulsions, suspensions, etc., or parenteral preparations such as topicals, suppositories, injections, drops, nasal preparations, pulmonary preparations, etc. In some embodiments, the pharmaceutical compositions are suitable for topical application such as ointments.

[0099] The pharmaceutical composition of the present invention may be prepared by mixing one or more crystalline forms of the present invention or the composition of the present invention with at least one or more pharma- ceutical acceptable carriers in a suitable amount according to methods known in the art of pharmaceutical formulation. The amount of Compound A in the pharmaceutical composition may be, for example, about 0.1 to 100% by weight of the composition, depending on its dosage form, dosage amount, etc. The pharmaceutical composition of the present invention may be in the form of, for example, a tablet, capsule, pill, powder, or ointment. In some embodiments, the pharmaceutical composition of the present invention may be in the form of a powder suitable for reconstitution into a liquid for intravenous (IV), intramuscular (IM), or subcutaneous (SC) administration. In addition, the pharmaceutical composition of the present invention may further comprise a second therapeutic agent.

[0100] The "pharmaceutical acceptable carrier" includes various conventional organic or inorganic carrier substances for medicinal materials, such as excipients, disintegrants, binders, flow agents, and lubricants for solid preparations, solvents, solubilizers, suspending agents, isotonicity agents, buffers, and soothing agents for liquid preparations, and bases, emulsifiers, moisturizing agents, stabilizers, dispersing agents, plasticizers, pH regulators, absorption promoters, gelling agents, preservatives, fillers, solubilizers, solubilizing agents, and suspending agents for semisolid preparations. Furthermore, additives such as preservatives, antioxidants, colorants, and sweeteners may be used as necessary.

[0101] Examples of excipients include lactose, sucrose, D-mannitol, D-sorbitol, corn starch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and gum arabic.

[0102] Examples of the disintegrant include carmellose, carmellose calcium, carmellose sodium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, and crystalline cellulose.

[0103] Examples of binders include hydroxypropyl cellulose, hydroxypropyl methylcellulose, povidone, crystalline cellulose, sucrose, dextrin, starch, gelatin, carmellose sodium, and gum arabic.

[0104] Examples of the flow agent include light anhydrous silicic acid, magnesium stearate, and the like.

[0105] Examples of lubricants include magnesium stearate, calcium stearate, talc, and the like.

[0106] Examples of solvents include purified water, ethanol, propylene glycol, macrogol, sesame oil, corn oil, and olive oil.

[0107] Examples of the solubilizing agent include propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate, and the like.

[0108] Examples of suspending agents include benzalkonium chloride, carmellose, hydroxypropyl cellulose, propylene glycol, povidone, methylcellulose, glyceryl monostearate, and the like.

[0109] Examples of the isotonicity agent include glucose, D-sorbitol, sodium chloride, D-mannitol, and the like.

[0110] Examples of buffering agents include sodium hydrogen phosphate, sodium acetate, sodium carbonate, sodium citrate, and the like.

[0111] An example of a soothing agent is benzyl alcohol.

[0112] Examples of preservatives include ethyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sorbic acid, and the like.

[0113] Examples of antioxidants include sodium sulfite, ascorbic acid, and the like.

[0114] Examples of coloring agents include food dyes (e.g., Food Red No. 2 or 3, Food Yellow No. 4 or 5, etc.), β-carotene, and the like.

[0115] Examples of sweeteners include sodium saccharin, dipotassium glycyrrhizinate, aspartame, and the like.

[0116] The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., partially, rectally, intravenously, etc.) in a therapeutically effective amount to a patient, such as a non-human mammal (e.g., mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, cow, horse, sheep, monkey, etc.) or human, for the treatment or prevention of a disease. The term "mammal" is meant to include both human and non-human mammalian subjects. The dosage of the pharmaceutical composition depends on the subject, disease, pathology, dosage form, and administration route. The dosage for oral administration to an adult patient (body weight: about 60 kg) suffering from rejection during organ transplantation, graft-versus-host reaction after transplantation, autoimmune disease, allergic disease, etc. may range, for example, from about 1 mg to 1 g / day. The dosage may be administered once or in several divided doses.

[0117] For topical pharmaceutical compositions, the carrier (or excipient) may include white petrolatum, solid paraffin, squalene, or a combination thereof. White petrolatum, solid paraffin, and squalene may be mixed in a mixing ratio of 70 to 90% by weight, 5 to 10% by weight, and 5 to 20% by weight, respectively. An example of a formulation includes compound A, white petrolatum, 5±2% by weight of solid paraffin, and 10±2% by weight of squalene.

[0118] The topical agent can be applied by painting, rubbing or spraying, for example, depending on the dosage form. The amount of the topical agent applied to the affected area can be selected depending on the content of the active ingredient, and the topical agent can be applied, for example, once a day or several times a day. In some embodiments, the application is once a day or twice a day.

[0119] Pharmaceutical compositions can be prepared in accordance with acceptable pharmaceutical procedures, such as those described in Remington's Pharmaceutical Sciences, 17th ed., Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference in its entirety.

[0120] The crystalline forms of the present invention can be used in a method of inhibiting a Janus kinase, such as JAK3, JAK2, or both, comprising contacting the crystalline forms of the present invention with a Janus kinase inhibitor. Contacting can occur in vitro or in vivo.

[0121] The crystalline forms or compositions of the invention may be used as an active ingredient in a method for the treatment or prevention of one or more of the following diseases in a patient: (a) Rejection during organ transplantation or graft-versus-host reaction after transplantation; (b) autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, type I diabetes mellitus, myasthenia gravis, Castleman's disease, juvenile idiopathic arthritis, dry eye, and the like; and (c) Allergic diseases such as asthma, atopic dermatitis, and rhinitis.

[0122] In some embodiments, the crystalline form of the present invention may be used as an active ingredient in an agent for the treatment or prevention of rheumatoid arthritis, psoriasis, alopecia areata, dry eye, atopic dermatitis, eczema, or hand eczema.

[0123] The crystalline form of the present invention may be used as an active ingredient of an agent for treating or preventing chronic myeloproliferative disorders such as polycythemia vera, primary myelofibrosis, and essential thrombocythemia.

[0124] As used herein, a "therapeutically effective amount" of a compound refers to an amount sufficient to cure, alleviate, or partially arrest the clinical symptoms of a given disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective amount." Effective amounts for each purpose depend on the severity of the disease or injury as well as the weight and general condition of the subject.

[0125] As used herein, the term "treatment" includes ameliorating symptoms, preventing exacerbations, maintaining remission, preventing exacerbations, and preventing recurrence. The term "treatment" may also include delaying the progression of a disease, disorder, or condition, ameliorating, alleviating, or reducing symptoms and complications, and / or curing or eliminating a disease, disorder, or condition.

[0126] The term "treatment" may also mean the management and care of a patient for the purpose of combating a disease, condition or disorder.

[0127] The term "prevention" means inhibiting the occurrence of a condition.

[0128] Combination therapy The crystalline forms of the present invention can be administered to a patient in combination with a therapeutically effective amount of one or more additional therapeutic agents. The crystalline forms of the present invention can be administered simultaneously (e.g., together) with the additional therapeutic agents (e.g., in a single fixed dosage form or in separate dosage forms). Similarly, the crystalline forms of the present invention and the additional therapeutic agents can be administered to a patient sequentially. For example, the additional therapeutic agent is administered while the crystalline forms of the present invention are exerting their therapeutic effect, or vice versa.

[0129] In order that the invention disclosed herein may be more effectively understood, the following examples are set forth below, which should be understood as being for illustrative purposes only and are not to be construed as limiting the invention in any manner whatsoever. EXAMPLES

[0130] Example 1 Preparation and characterization of α-crystals of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A) Preparation of Compound A Compound A was prepared by the following synthetic method described in International Patent Application No. PCT / JP2016 / 070046 (Examples 1 to 15). In the crystallization step, seed crystals were used to promote crystallization, but crystals of each compound can be prepared according to the described method without using seed crystals.

[0131] As used herein, the abbreviations have the following meanings: S-BAPO: (S)-2-(benzylamino)propan-1-ol S-BBMO: (S)-N-benzyl-N-(1-hydroxypropan-2-yl)glycinate tert-butyl R-BCAB: (R)-N-benzyl-N-(2-chloropropyl)glycinate tert-butyl S-MABB: (3S)-1-benzyl-3-methylazetidine-2-carboxylate tert-butyl S-MABB-HC: (3S)-1-benzyl-3-methylazetidine-2-carboxylate tert-butyl hydrochloride S-MACB-HC: (3S)-3-Methylazetidine-2-carboxylate tert-butyl hydrochloride S-ZMAB: (3S)-3-Methylazetidine-1,2-dicarboxylate 1-benzyl 2-(tert-butyl) RS-ZMBB: (2R,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-methylazetidine-1,2-dicarboxylate 1-benzyl 2-(tert-butyl) RS-ZMAA: (2R,3S)-1-((benzyloxy)carbonyl)-2-(carboxymethyl)-3-methylazetidine-2-carboxylic acid RS-ZMAA-DN·2H2O: (2R,3S)-1-((benzyloxy)carbonyl)-2-(carboxymethyl)-3-methylazetidine-2-carboxylic acid disodium salt dihydrate RS-ZMOO: (2R,3S)-2-(2-hydroxyethyl)-2-(hydroxymethyl)-3-methylazetidine-1-carboxylate benzyl RS-ZMSS: (2R,3S)-3-methyl-2-(2-((methylsulfonyl)oxy)ethyl)-2-(((methylsulfonyl)oxy)methyl)azetidine-1-carboxylate benzyl SR-ZMDB: (3S,4R)-6-benzyl-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylate benzyl SR-MDOZ: (3S,4R)-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylate benzyl SR-MDOZ-OX: (3S,4R)-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylic acid benzyl oxalate SR-MDPZ: (3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane-1-carboxylate benzyl SR-MDOP: 4-[(3S,4R)-3-methyl-1,6-diazaspiro[3.4]-octan-6-yl]-7H-pyrrolo[2,3-d]pyrimidine Compound A: 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile CPPY: 4-chloro-7H-pyrrolo[2,3-d]pyrimidine DPCN: 1-cyanoacetyl-3,5-dimethyl-1H-pyrazole TBBA: Bromoacetic acid tert-butyl ester THF: tetrahydrofuran

[0132] The measurement apparatus and conditions used are as follows. 1 H-NMR spectra were measured in CDCl3 or DMSO-d6 using tetramethylsilane as an internal standard, and all δ values ​​are shown in ppm. Unless otherwise stated, a 400 MHz NMR instrument was used. The symbols in the examples have the following meanings. s: singlet d: doublet t: triplet q:Quartet dd: double doublet ddd: double doublet brs: broad singlet m:Multiplet J: Coupling constant The ion content in the sample was determined by averaging the three measurements. Measurement equipment: Ion chromatograph LC-20 system (SHIMADZU) Measurement conditions: Electrical conductivity detector SHIMADZU CDD-10A VP Anion analysis column SHIMADZU SHIM-PAC IC-A3 Cation analysis column SHIMADZU SHIM-PAC IC-C1 The water content in the samples was determined by the Karl Fischer method. Measurement equipment: Karl Fischer moisture meter CA-06 (MITSUBISHI CHEMICAL) Measurement conditions: Sample size: approx. 20mg Reagent: Anolyte Aquamicron AX (API Corporation) Catholyte Aquamicron CXU (API Corporation) Elemental analysis was used to determine the weight percentages of carbon, hydrogen and nitrogen in the samples.

[0133] Step 1. Preparation of AS-MABB-HC (compound [5]) [ka] Process 1 [ka] Under a nitrogen atmosphere, S-BAPO[1] (35.0 g, 212 mmol) was added to water (175 mL) at room temperature. Toluene (53 mL) and potassium carbonate (32.2 g, 233 mmol) were added to this suspension at room temperature. TBBA (434.4 g, 223 mmol) was added dropwise to this solution at room temperature, the dropping funnel used was washed with toluene (17 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at 65 ° C for 21 hours and then cooled to room temperature. Toluene (105 mL) was added to the reaction mixture and stirred, and the organic layer was separated. The obtained organic layer was washed with water (175 mL), the aqueous layer was discharged, and the solvent of the organic layer was distilled off under reduced pressure. Toluene (105 mL) was added to this concentrated residue and concentrated. This operation was repeated two more times, and a toluene solution of S-BBMO[2] (equivalent to 74.0 g, 212 mmol) was obtained. The obtained toluene solution of S-BBMO was used in the next step with a yield of 100%. The crude S-BBMO product synthesized in the same manner was concentrated to dryness and subjected to NMR and MS measurements. 1 H-NMR (DMSO-d6) δ: 7.36-7.13 (5H, m), 4.26 (1H, dd, J = 6.8, 3.9 Hz), 3.72 (2H, dd, J = 14.2, 6.8 Hz), 3.47-3.38 (1H, m), 3.30-3.08 (3H, m), 2.79 (1H, sext, J = 6.8 Hz), 1.35 (9H, s), 0.96 (3H, d, J = 6.8 Hz). MS: m / z = 280 [M+H] +

[0134] Process 2 [ka] Under a nitrogen atmosphere, toluene (200 mL), tetrahydrofuran (35 mL), and triethylamine (25.7 g, 254 mmol) were added to a toluene solution of S-BBMO[2] (74.0 g, 212 mmol) at room temperature. Methanesulfonyl chloride (26.7 g, 233 mmol) was added dropwise to this mixture at 0°C, the dropping funnel used was washed with toluene (10 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours, and then stirred at 65°C for 22 hours, and then cooled to room temperature. Sodium bicarbonate water (105 mL) was added to the reaction mixture and stirred, and the organic layer was separated. The obtained organic layer was washed with water (105 mL), the aqueous layer was discharged, and the solvent of the organic layer was distilled off under reduced pressure. Toluene (105 mL) was added to the concentrated residue and concentrated. After repeating this procedure two more times, a toluene solution of R-BCAB[3] (75.3 g, 212 mmol) was obtained. The obtained toluene solution of R-BCAB was used in the next step as a 100% yield. The crude R-BCAB product synthesized in the same manner was concentrated to dryness and subjected to NMR and MS measurements. 1 H-NMR (DMSO-d6) δ: 7.28-7.11 (5H, m), 4.24-4.11 (1H, m), 3.80 (2H, d, J = 3.6 Hz), 3.24 (2H, d, J = 3.6 Hz), 2.98-2.78 (2H, m), 1.46-1.37 (12H, m). MS: m / z = 298 [M+H] +

[0135] Process 3 [ka] Under a nitrogen atmosphere, tetrahydrofuran (88.0 mL) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (42.0 mL) were added to a toluene solution of R-BCAB[3] (75.3 g, 212 mmol) at room temperature. A lithium bis(trimethylsilyl)amide / tetrahydrofuran solution (195 mL, 233 mmol) was added dropwise to this solution at 0°C, the dropping funnel used was washed with tetrahydrofuran (17.0 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at 0°C for 1 hour and then warmed to room temperature. Water (175 mL) and toluene (175 mL) were added to the reaction mixture and stirred, and the organic layer was separated. The obtained organic layer was washed successively with an aqueous ammonium chloride solution (175 mL) and water (175 mL), and the solvent of the organic layer was distilled off under reduced pressure. Ethyl acetate (175 mL) was added to the concentrated residue and concentrated. This procedure was repeated two more times to obtain an ethyl acetate solution of S-MABB [4] (66.5 g, equivalent to 212 mmol). The obtained ethyl acetate solution of S-MABB was used in the next step as a 100% yield. The crude product of S-MABB synthesized in the same manner was concentrated to dryness and subjected to NMR and MS analysis. 1 H-NMR (DMSO-d6) δ: 7.28-7.25 (10H, m), 3.75 (1H, d, J = 12.7 Hz), 3.68 (1H, d, J = 1.4 Hz), 3.66 (1H, d, J = 6.7 Hz), 3.46 (2H, d, J = 12.7 Hz), 3.30-3.17 (2H, m), 2.95 (1H, dd, J = 6.2, 1.2 Hz), 2.77 (1H, dd, J = 6.1, 2.2 Hz), 2.65-2.55 (1H, m), 2.48-2.40 (2H, m), 1.35 (9H, s), 1.35 (9H, s), 1.12 (3H, d, J = 7.2 Hz), 1.09 (3H, d, J = 6.2 Hz). MS: m / z = 262 [M+H] +

[0136] Process 4 [ka] Under a nitrogen atmosphere, ethyl acetate (175 mL) and activated carbon (3.5 g) were added to an ethyl acetate solution of S-MABB [4] (equivalent to 66.5 g, 212 mmol) and stirred at room temperature for 2 hours. The activated carbon was removed by filtration, the filtration residue was washed with ethyl acetate (175 mL), and the washings were added to the filtrate. Crystals of S-MABB-HC (17.5 mg) prepared according to this method were added to this solution at 0 °C, and then 4 M hydrogen chloride / ethyl acetate solution (53.0 mL, 212 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 17 hours, and the precipitated solid was filtered and washed with ethyl acetate (70 mL). The obtained wet solid was dried under reduced pressure to obtain S-MABB-HC [5] (48.3 g, 162 mmol) in a yield of 76.4%. The NMR, MS and Cl content of S-MABB-HC synthesized in the same manner were measured. 1 H-NMR (DMSO-d6) δ: 11.08 (1H, br s), 10.94 (1H, br s), 7.52-7.42 (10H, m), 5.34 (1H, t, J = 8.4 Hz), 4.90 (1H, br s), 4.45-4.10 (5H, m), 3.92-3.49 (3H, br m), 3.10-2.73 (2H, br m), 1.35 (9H, s), 1.29 (9H, s), 1.24 (3H, d, J = 6.7 Hz), 1.17 (3H, d, J = 7.4 Hz). MS: m / z = 262 [M+H-HCl] + Cl content (ion chromatography): 11.9% (theoretical value: 11.9%)

[0137] Step 1. Preparation of BS-MACB-HC (compound [6]) [ka] Under a nitrogen atmosphere, 5% palladium carbon (KAWAKEN Fine Chemicals PH type, 54.1% water content, 1.0 g) was added to a methanol (15.0 mL) solution of S-MABB-HC [5] (5.0 g, 16.8 mmol) at room temperature. The reaction vessel was replaced with hydrogen, and the mixture was stirred at room temperature for 12 hours under a hydrogen gas pressure of 0.4 MPa. The reaction vessel was then replaced with nitrogen, and the 5% palladium carbon was removed by filtration. The reaction vessel and 5% palladium carbon were washed with methanol (10 mL). The washings were added to the filtrate to obtain a methanol solution of S-MACB-HC [6] (equivalent to 24.8 g, 16.8 mmol). The obtained methanol solution of S-MACB-HC was used in the next step as a 100% yield. The crude product of S-MACB-HC synthesized by the same method was concentrated to dryness and subjected to NMR and MS measurements. 1 H-NMR (DMSO-d6) δ: 9.60 (br s, 1H), 4.97 (d, 1H, J = 9.2 Hz), 4.61 (d, 1H, J = 8.4 Hz), 4.01 (dd, 1H, J = 10.0, 8.4 Hz), 3.78-3.74 (m, 1H), 3.54 (dd, 1H, J = 9.6, 8.4 Hz), 3.35 (dd, 1H, J = 10.0, 6.0 Hz), 3.15-3.03 (m, 1H), 3.00-2.88 (m, 1H), 1.49 (s, 9H), 1.47 (s, 9H), 1.22 (d, 3H, J = 6.8 Hz), 1.14 (d, 3H, J = 7.2 Hz). MS: m / z = 172 [M+H] + (Free form)

[0138] Step 1. Preparation of CS-ZMAB (compound [7]) [ka] Under a nitrogen atmosphere, N,N-diisopropylethylamine (4.8 g, 36.9 mmol) was added dropwise to a methanol solution (equivalent to 24.8 g, 16.8 mmol) of S-MACB-HC[6] at room temperature, the dropping funnel used was washed with tetrahydrofuran (2.5 mL), and the washings were added to the reaction mixture. Benzyl chloroformate (3.0 g, 17.6 mmol) was added dropwise to this reaction mixture at 0°C, the dropping funnel used was washed with tetrahydrofuran (2.5 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at 0°C for 1 hour, and the solvent was distilled off under reduced pressure. Toluene (25.0 mL) and citric acid water (25.0 mL) were added to the obtained concentrated residue, and the mixture was stirred, and the organic layer was separated. The obtained organic layer was washed successively with sodium bicarbonate water (25.0 mL) and water (25.0 mL), and the solvent of the organic layer was distilled off under reduced pressure. Toluene (15.0 mL) was added to the concentrated residue and concentrated. This operation was repeated once more. After the concentration was completed, a toluene solution of S-ZMAB [7] (6.9 g, equivalent to 16.8 mmol) was obtained. The obtained toluene solution of S-ZMAB was used in the next step as a 100% yield. The crude S-ZMAB product synthesized in the same manner was concentrated to dryness and subjected to NMR and MS measurements. 1 H-NMR (CDCl3) δ: 7.38-7.28 (m, 10H), 5.16-5.04 (m, 4H), 4.60 (d, 1H, J = 9.2 Hz), 4.18-4.12 (m, 2H), 4.04 (t, 1H, J = 8.6 Hz), 3.66 (dd, 1H, J = 7.6, 7.2 Hz), 3.50 (dd, 1H, J = 8.0, 5.2 Hz), 3.05-2.94 (m, 1H), 2.60-2.50 (m, 1H), 1.43 (br s, 18H), 1.33 (d, 3H, J = 6.5 Hz), 1.15 (d, 3H, J = 7.2 Hz). MS: m / z = 328 [M+Na] + .

[0139] Step D. Preparation of RS-ZMBB (compound [8]) [ka] Under a nitrogen atmosphere, tetrahydrofuran (15.0 mL) was added to a toluene solution (6.9 g, 16.8 mmol) of S-ZMAB [7] at room temperature. Lithium bis(trimethylsilyl)amide / tetrahydrofuran solution (14.7 mL, 17.6 mmol) was added dropwise to this solution at -70 ° C. The dropping funnel used was washed with tetrahydrofuran (2.5 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at -70 ° C for 6 hours, and then TBBA (3.4 g, 17.6 mmol) diluted with tetrahydrofuran (2.5 mL) was added dropwise at -70 ° C. The dropping funnel used was washed with tetrahydrofuran (2.5 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at -70 ° C for 1 hour, then warmed to room temperature, and ammonium chloride water (25 mL) and toluene (25 mL) were added and stirred, and the organic layer was separated. The organic layer was washed twice with citric acid (25 mL), sodium bicarbonate (25 mL), and water (25 mL), and then the solvent in the organic layer was removed under reduced pressure. Acetonitrile (15 mL) was added to the concentrated residue, and the mixture was concentrated again. This operation was repeated two more times. Acetonitrile (15 mL) and activated carbon (0.25 g) were added to the concentrated residue, and the mixture was stirred at room temperature for 2 hours. The activated carbon was removed by filtration, and the reaction vessel and the filtration residue were washed with acetonitrile (10 mL). The filtrate and the washings were combined, and the solvent was removed under reduced pressure to obtain an acetonitrile solution of RS-ZMBB[8] (13.2 g, equivalent to 16.8 mmol). The obtained acetonitrile solution of RS-ZMBB was used in the next step as a 100% yield. The crude RS-ZMBB product synthesized in the same manner was concentrated to dryness and subjected to NMR and MS measurements. 1H-NMR (DMSO-d6) δ: 7.38-7.29 (m, 5H), 5.09-4.96 (m, 2H), 3.91 (t, 0.4H, J = 8.0 Hz), 3.79 (t, 0.6H, J = 8.0 Hz), 3.55 (t, 0.4H, J = 7.2 Hz), 3.46 (t, 0.6H, J = 7.5 Hz), 3.14-3.04 (m, 1H), 2.83-2.72 (m, 2H), 1.38 (br s, 9H), 1.37 (br s, 3.6H), 1.34 (br s, 5.4H), 1.12-1.09 (m, 3H). MS: m / z = 420 [M+H] + .

[0140] Process E.RS-ZMAA-DN·2H 2 Preparation of O (compound [9]) [ka] Acetonitrile (15 mL) was added to an acetonitrile solution of RS-ZMBB [8] (13.2 g, 16.8 mmol) at room temperature under a nitrogen atmosphere. p-Toluenesulfonic acid monohydrate (6.4 g, 33.6 mmol) was added to this solution at room temperature. The reaction mixture was stirred at 50 ° C for 12 hours, cooled to room temperature, and water (7.5 mL) was added dropwise. The reaction mixture was cooled to 0 ° C, and 4 mol / L sodium hydroxide aqueous solution (17.6 mL, 70.5 mmol) was added dropwise. After stirring at room temperature for 1 hour, acetonitrile (75 mL) was added dropwise at room temperature and stirred for 3 hours. The precipitated solid was collected by filtration, and the obtained solid was washed successively with a mixture solution (10 mL) of acetonitrile: water = 4: 1 and acetonitrile (10 mL). The obtained wet solid was dried under reduced pressure to obtain RS-ZMAA-DN 2H2O[9] (5.2 g, 13.4 mmol) in a yield of 85.4%. The NMR, MS, Na content and water content of RS-ZMAA-DN·2H2O synthesized by the same method were measured. 1H-NMR (DMSO-d6) δ: 7.32-7.22 (m, 5H), 4.97 (d, 1H, J = 12.7 Hz), 4.84 (d, 1H, J = 12.7 Hz), 3.79 (t, 1H, J = 8.0 Hz), 3.29 (d, 1H, J = 14.8 Hz), 3.16-3.12 (m, 1H), 2.17-2.09 (m, 2H), 1.07 (d, 3H, J = 6.9 Hz). MS: m / z = 352 [M+H] + (anhydride) Na content (ion chromatography): 13.3% (after water content correction) (theoretical value: 13.1%) Moisture content (Karl Fischer method): 9.8% (theoretical value: 9.3%)

[0141] Step F. Preparation of RS-ZMAA (compound

[10] ) [ka] RS-ZMAA-DN·2H2O[9] (30 g, 77.5 mmol) and acetonitrile (60 mL) were added to 1 mol / L hydrochloric acid (180 mL) and stirred at room temperature for about 15 minutes. Ethyl acetate (240 mL) was added to this reaction mixture and further stirred, and the organic layer was separated. The organic layer was washed twice with 10% saline (60 mL). Magnesium sulfate (6 g) was added to the organic layer and stirred, and the magnesium sulfate was filtered, and the filtration residue was washed with ethyl acetate (60 mL). The filtrate and washings were combined, and the solvent was distilled off under reduced pressure. Tetrahydrofuran (240 mL) was added to this concentrated residue and concentrated under reduced pressure. This operation was repeated two more times. Tetrahydrofuran (60 mL) was added to this concentrated residue to obtain a tetrahydrofuran solution of RS-ZMAA

[10] . The obtained tetrahydrofuran solution of RS-ZMAA was used in the next step as a 100% yield. NMR and MS were measured for RS-ZMAA synthesized by the same method. 11H-NMR (DMSO-D6) δ: 7.35 - 7.28 (m, 5H), 5.06 - 4.94 (m, 2H), 3.86 (dt, 1H, J = 48.4, 7.9 Hz), 3.50 (dt, 1H, J = 37.9, 7.4 Hz), 3.16 - 3.02 (br m, 1H), 2.91 - 2.77 (br m, 2H), 1.08 (d, 3H, J = 6.9 Hz) MS: m / z = 308 [M+H] + .

[0142] Step G. Preparation of RS-ZMOO (compound

[11] )

Chem.

[10] (equivalent to 25.8 mmol), and boron trifluoride diethyl ether complex (4.40 g) was added dropwise at 0 to 5 ° C. The dropping funnel was washed with tetrahydrofuran (5 mL), and the washings were added to the reaction mixture. 1.2 mol / L borane-tetrahydrofuran complex (43.0 mL) was added dropwise to the reaction mixture at 0 to 5 ° C., and the mixture was stirred at 0 to 5 ° C. for about 30 minutes, and then further stirred at room temperature overnight. 1.2 mol / L borane-tetrahydrofuran complex (21.1 mL) was added dropwise to the reaction mixture at 0 to 5 ° C., and the mixture was stirred at room temperature overnight. After stirring, water (40 mL) was added dropwise to the reaction mixture at 0 to 15 ° C. Sodium bicarbonate (5.42 g) was added to the reaction mixture at 0°C to 15°C, the sodium bicarbonate adhering to the container was washed with water (10 mL), and the washing solution was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours, and then toluene (50 mL) was added and further stirred. The organic layer was separated. The obtained organic layer was washed once with 20 mL of 10% saline, three times with a mixed solution of 5% sodium bicarbonate water (20 mL) and 10% saline (20 mL), once with a mixed solution of 5% potassium hydrogen sulfate aqueous solution (10 mL) and 10% saline (10 mL), and twice with 10% saline (20 mL). Magnesium sulfate (8.9 g) was added to the organic layer and stirred, after which the magnesium sulfate was filtered, and the filtration residue was washed with toluene (20 mL). This washing solution was added to the filtrate, and the solvent of the filtrate was distilled off under reduced pressure. Toluene (80 mL) was added to the concentrated residue, concentrated under reduced pressure, and toluene (15 mL) was added to obtain a toluene solution of RS-ZMOO

[11] . The obtained toluene solution of RS-ZMOO was used in the next step as a 100% yield. NMR and MS were measured for RS-ZMOO synthesized by the same method. 1H-NMR (CDCl3) δ: 7.39-7.30 (m, 5H), 5.10 (s, 2H), 4.15-4.01 (br m, 2H), 3.83-3.73 (br m, 3H), 3.48 (dd, 1H, J = 8.3, 6.4 Hz), 2.59-2.50 (br m, 1H), 2.46-2.40 (br m, 1H), 2.07-1.99 (m, 1H), 1.14 (d, 3H, J = 7.2 Hz) MS: m / z = 280 [M+H] + .

[0143] Step H. Preparation of RS-ZMSS (compound

[12] ) [ka] Under a nitrogen atmosphere, toluene (55 mL) was added to a toluene solution of RS-ZMOO

[11] (equivalent to 23.7 mmol), triethylamine (5.27 g) was added dropwise at -10 to 10 °C, the dropping funnel was washed with toluene (1.8 mL), and the washings were added to the reaction mixture. Methanesulfonyl chloride (5.69 g) was added dropwise to this reaction mixture at -10 to 10 °C, the dropping funnel was washed with toluene (1.8 mL), and the washings were combined with the reaction mixture. The reaction mixture was stirred at 0 to 10 °C for about 2 hours, and then water (28 mL) was added dropwise at 0 to 20 °C. The reaction mixture was stirred at 0 to 20 °C for about 30 minutes, and the organic layer was separated. The obtained organic layer was washed twice with 10% saline (18 mL). Magnesium sulfate (2.75 g) was added to the obtained organic layer and stirred, after which the magnesium sulfate was filtered and the filtration residue was washed with toluene (18 mL). The washing liquid was added to the filtrate, and the solvent of the filtrate was distilled off under reduced pressure. Toluene was added to the concentrated residue to make about 18 mL, and a toluene solution of RS-ZMSS

[12] was obtained. The obtained toluene solution of RS-ZMSS was used in the next step as a 100% yield. NMR and MS were measured for RS-ZMSS synthesized by the same method. 11H-NMR (DMSO-D6) δ: 7.37 - 7.27 (broad multiplet, 5H), 5.10 - 4.98 (multiplet, 2H), 4.58 - 4.22 (broad multiplet, 4H), 3.84 (doublet of triplets, 1H, J = 45.6, 8.1 Hz), 3.48 - 3.33 (broad multiplet, 1H), 3.17 - 3.10 (multiplet, 6H), 2.81 - 2.74 (broad multiplet, 1H), 2.22 - 2.12 (multiplet, 2H) MS: m / z = 436 [M+H] + .

[0144] Step I. Preparation of SR-ZMDB (compound

[13] )

Chem.

[12] (equivalent to 23.7 mmol) under a nitrogen atmosphere, and benzylamine (17.8 g) was added dropwise at room temperature. The dropping funnel was washed with toluene (9.2 mL), and the washings were added to the reaction mixture. This reaction mixture was stirred at room temperature for about 1 hour, at 55 to 65 °C for about 3 hours, and then at 70 to 80 °C for about 6 hours. After cooling the reaction mixture to room temperature, 10% NaCl (28 mL) was added dropwise and stirred at room temperature for about 30 minutes. Toluene (37 mL) was added to the reaction mixture, which was then stirred, and the organic layer was separated. The obtained organic layer was washed twice with a solution of 10% saline (18 mL) and acetic acid (2.84 g), and once with 10% saline (11 mL), in that order. The solvent in the organic layer was distilled off under reduced pressure until the residue was reduced to half its volume, and then acetic anhydride (1.45 g) was added to the concentrated residue at room temperature and stirred for about 3 hours. A solution of potassium hydrogen sulfate (3.87 g) and water (92 mL) was added dropwise to the reaction mixture at room temperature, and the mixture was stirred. The aqueous layer was separated. The aqueous layer was washed with toluene (18 mL), and then toluene (73 mL) and sodium bicarbonate (6.56 g) were added successively at room temperature and stirred. The organic layer was separated and washed with 10% saline (11 mL). Magnesium sulfate (2.75 g) was added to the organic layer and stirred, and the magnesium sulfate was filtered. The filtration residue was washed with toluene (18 mL), and the filtrate and washings were combined and the solvent was distilled off under reduced pressure. Toluene (44 mL) was added to the concentrated residue to obtain a toluene solution of SR-ZMDB

[13] . The toluene solution of SR-ZMDB was used in the next step as a 100% yield. 1 H-NMR (CDCl3) δ: 7.35-7.20 (m, 10H), 5.08 (d, 2H, J = 23.6 Hz), 3.94 (q, 1H, J = 7.9 Hz), 3.73-3.42 (br m, 2H), 3.30-3.23 (m, 1H), 3.05 (dd, 1H, J = 19.7, 9.5 Hz), 2.79 (dt, 1H, J = 69.6, 6.1 Hz), 2.57-2.32 (br m, 4H), 1.96-1.89 (m, 1H), 1.09 (d, 3H, J = 6.9 Hz) MS: m / z = 351 [M+H]+ .

[0145] Step J. Preparation of SR-MDOZ (compound

[14] ) [ka] Under a nitrogen atmosphere, a solution of SR-ZMDB

[13] in toluene (equivalent to 23.7 mmol) was added dropwise to a solution of 1-chloroethyl chloroformate (3.72 g) and toluene (28 mL) at 0 to 10 °C, the dropping funnel was washed with toluene (4.6 mL), and the washings were added to the reaction mixture. Triethylamine (718 mg) was added to the reaction mixture at 0 to 10 °C, and the mixture was stirred at 15 to 25 °C for about 2 hours, after which methyl alcohol (46 mL) was added and the mixture was stirred at 50 to 60 °C for another 2 hours. The solvent of the reaction mixture was distilled under reduced pressure until the residue was about 37 mL or less. 2 mol / L hydrochloric acid water (46 mL) was added dropwise to the concentrated residue at 15 to 20 °C and stirred, and the aqueous layer was separated. The obtained aqueous layer was washed twice with toluene (28 mL). After adding 20% ​​saline (46 mL) and tetrahydrofuran (92 mL) to the aqueous layer, 8 mol / L sodium hydroxide solution (18 mL) was added dropwise at 0 to 10 °C. The organic layer was separated from the reaction mixture, washed twice with 20% saline (18 mL), and the solvent of the organic layer was distilled off under reduced pressure. Tetrahydrofuran (92 mL) was added to the concentrated residue and concentrated under reduced pressure. This operation was performed one more time. Tetrahydrofuran (92 mL) was added to the concentrated residue to dissolve it, magnesium sulfate (2.75 g) was added and stirred, and then magnesium sulfate was filtered. The filtered residue was washed with tetrahydrofuran (28 mL), and the filtrate and washings were combined and the solvent was distilled off under reduced pressure. The volume of this concentrated residue was adjusted to about 20 mL with tetrahydrofuran, and a tetrahydrofuran solution of SR-MDOZ

[14] (net amount 4.01 g, 15.4 mol) was obtained in a yield of 65.0%. SR-MDOZ synthesized in the same manner was concentrated to dryness and subjected to NMR and MS measurements. 1H-NMR (CDCl3) δ: 7.37-7.28 (m, 5H), 5.08 (dd, 2H, J = 16.8, 12.8 Hz), 4.00 (dd, 1H, J = 17.1, 8.3 Hz), 3.40-3.31 (m, 1H), 3.24 (d, 1H, J = 12.7 Hz), 3.00 (dd, 1H, J = 54.9, 12.4 Hz), 2.87-2.57 (m, 3H), 2.47-2.27 (m, 1H), 1.91-1.80 (m, 1H), 1.14 (d, 3H, J = 7.2 Hz) MS: m / z = 261 [M+H] + .

[0146] Step K. Preparation of SR-MDOZ-OX (compound

[15] ) [ka] Under a nitrogen atmosphere, oxalic acid (761 mg) was dissolved in tetrahydrofuran (40 mL) and a solution of SR-MDOZ

[14] in tetrahydrofuran (equivalent to 3.84 mmol) was added dropwise at room temperature. The crystals of SR-MDOZ-OX (1 mg) prepared according to this method were added to this solution at room temperature and stirred at room temperature for about 3.5 hours to precipitate crystals. A solution of SR-MDOZ in tetrahydrofuran (3.84 mmol) was added dropwise to this slurry at room temperature and stirred at room temperature for about 1 hour. This slurry was heated and stirred at 50 to 60 ° C for about 2 hours, and then stirred at room temperature overnight. This slurry was filtered, and the wet crystals were washed with tetrahydrofuran (10 mL) and dried under reduced pressure to obtain SR-MDOZ-OX

[15] (2.32 g, 6.62 mol) in a yield of 86.2%. NMR, MS and elemental analysis of SR-MDOZ-OX synthesized by the same method were carried out. 1H-NMR (DMSO-D6) δ: 7.37-7.30 (m, 5H), 5.15-5.01 (m, 2H), 3.92 (dt, 1H, J = 43.5, 8.4 Hz), 3.48-3.12 (br m, 5H), 2.67-2.56 (m, 1H), 2.46-2.35 (m, 1H), 2.12-2.05 (m, 1H), 1.13 (d, 3H, J = 6.9 Hz) MS: m / z = 261 [M+H] + Elemental analysis: C 58.4wt%, H 6.4wt%, N 7.9wt% (theoretical values: C 58.3wt%, H 6.3wt%, N 8.0wt%)

[0147] Step L. Preparation of SR-MDPZ (compound

[16] ) [ka] Ethanol (36 mL) was added to SR-MDOZ-OX

[15] (12.0 g, 34.2 mmol) under a nitrogen atmosphere, followed by water (72 mL), CPPY

[20] (5.36 g, 34.9 mmol) and K3PO4 (21.8 g, 103 mmol) in that order. The reaction mixture was stirred at 80°C for 5 hours, cooled to 40°C, and toluene (120 mL) was added at 40°C to separate the organic layer. The organic layer was washed with 20% potassium carbonate aqueous solution (48 mL), and then washed twice with water (48 mL). The solvent in the organic layer was then distilled off under reduced pressure. Tert-butanol (60 mL) was added to the concentrated residue and concentrated. This operation was repeated two more times. To the concentrated residue, tert-butanol (36 mL) was added to obtain a tert-butanol solution of SR-MDPZ

[16] (61.1 g, 34.2 mmol equivalent). The obtained tert-butanol solution of SR-MDPZ was used in the next step as a 100% yield. SR-MDPZ synthesized by the same method was isolated as a solid using a mixed solvent of ethyl acetate and n-heptane, and its NMR and MS spectra were measured. 11H-NMR (DMSO-d6) δ: 11.59 (broad singlet, 1H), 8.08 (singlet, 1H), 7.41 - 7.26 (broad multiplet, 3H), 7.22 - 7.08 (broad multiplet, 3H), 6.64 - 6.51 (broad multiplet, 1H), 5.07 - 4.91 (broad multiplet, 2H), 4.09 - 3.67 (broad multiplet, 5H), 3.47 - 3.32 (broad multiplet, 1H), 2.67 - 2.55 (broad multiplet, 2H), 2.21 - 2.15 (broad multiplet, 1H), 1.11 (doublet, 3H, J = 6.9 Hz). MS: m / z = 378 [M+H] +

[0148] Step M. Preparation of SR-MDOP (compound

[17] )

Chem.

[16] (equivalent to 34.2 mmol). The reaction mixture was stirred at 40 °C for 13 hours, cooled to room temperature, and insoluble matter was removed by filtration. The reaction vessel and insoluble matter were washed with tert-butanol (24 mL), and 8 M aqueous sodium hydroxide solution (25.7 mL, 205 mmol) and sodium chloride (13.2 g) were added to the washings and filtrate. The reaction mixture was stirred at 50 °C for 2 hours, and then toluene (84 mL) was added at room temperature to separate the organic layer. The obtained organic layer was washed with 20% saline (60 mL), and then anhydrous sodium sulfate was added and stirred, after which the sodium sulfate was filtered off. The filtration residue was washed with a toluene: tert-butanol = 1: 1 mixed solution (48 mL), and the filtrate and washings were combined to remove the solvent under reduced pressure. Toluene (60 mL) was added to the concentrated residue, and the mixture was stirred at 50 ° C for 2 hours, and then the solvent was removed under reduced pressure. Toluene (60 mL) was added again to the concentrated residue to concentrate it. Toluene (48 mL) was added to the concentrated residue, and the mixture was stirred at room temperature for 1 hour, and then under ice cooling for 1 hour. The precipitated solid was filtered, and the obtained solid was washed with toluene (24 mL). The obtained wet solid was dried under reduced pressure to obtain SR-MDOP

[17] (7.07 g, 29.1 mmol) in a yield of 84.8%. NMR and MS of SR-MDOP synthesized by the same method were measured. 1 H-NMR (DMSO-d6) δ: 11.57 (br s, 1H), 8.07 (s, 1H), 7.10 (d, 1H, J = 3.2 Hz), 6.58 (d, 1H, J = 3.2 Hz), 3.92-3.59 (br m, 4H), 3.49 (dd, 1H, J = 8.3, 7.2 Hz), 2.93 (dd, 1H, J = 7.2, 6.1 Hz), 2.61-2.53 (m, 2H), 2.12-2.01 (br m, 2H), 1.10 (d, 3H, J = 6.9 Hz). MS: m / z = 244 [M+H] +.

[0149] Step N. Preparation of 1-ethanol solvate of compound A (compound

[18] ) [ka] Under a nitrogen atmosphere, acetonitrile (60 mL) and triethylamine (416 mg, 4.11 mmol) were added to SR-MDOP

[17] (5.00 g, 20.5 mmol), and then a solution of DPCN

[21] (3.69 g, 22.6 mmol) in acetonitrile (35 mL) was added dropwise at 45 ° C., the dropping funnel used was washed with acetonitrile (5.0 mL), and the washings were added to the reaction mixture. The reaction mixture was stirred at 45 ° C. for 3 hours, and then cooled to room temperature. After the reaction, 5% sodium bicarbonate water (25 mL), 10% saline (25 mL), and ethyl acetate (50 mL) were added to the mixture, and the mixture was stirred, and the organic layer was separated. The solvent of the organic layer was distilled off under reduced pressure. Tetrahydrofuran (50 mL) was added to the concentrated residue and concentrated. This operation was repeated three more times. Tetrahydrofuran (50 mL) was added to the concentrated residue, water was added so that the water content of the solution became 5.5%, and the precipitated insoluble matter was removed by filtration. The reaction vessel and the filtration residue were washed with tetrahydrofuran (15 mL), the washing liquid was added to the filtrate, and the solvent of the filtrate was distilled off under reduced pressure. Ethanol (50 mL) and crystals of compound A (5.1 mg) prepared by the method of Example 15 below were added to the concentrated residue, and the mixture was stirred at room temperature for 1 hour, after which the solvent was distilled off under reduced pressure, ethanol (50 mL) was added, and the mixture was concentrated again. Ethanol (15 mL) was added to the concentrated residue, and the mixture was stirred at room temperature for 1 hour. The precipitated solid was collected by filtration, and the obtained solid was washed with ethanol (20 mL). The obtained wet solid was dried under reduced pressure to obtain 1-ethanol solvate of compound A

[18] (6.26 g, 17.6 mmol) in a yield of 85.5%. The NMR and MS of the 1-ethanol solvate of compound A, which was synthesized by the same method, were measured. 1H-NMR (DMSO-d6) δ: 11.59 (br s, 1H), 8.08 (s, 1H), 7.11 (dd, 1H, J = 3.5, 2.3 Hz), 6.58 (dd, 1H, J = 3.5, 1.8 Hz), 4.34 (t, 1H, J = 5.1 Hz), 4.16 (t, 1H, J = 8.3 Hz), 4.09-3.92 (m, 3H), 3.84-3.73 (m, 1H), 3.71 (d, 1H, J = 19.0 Hz), 3.65 (d, 1H, J = 19.0 Hz), 3.58 (dd, 1H, J = 8.2, 5.9 Hz), 3.44 (dq, 2H, J = 6.7, 5.1 Hz), 2.69-2.60 (m, 2H), 2.23-2.13 (br m, 1H), 1.12 (d, 3H, J = 7.1 Hz), 1.06 (t, 3H, J = 6.7 Hz). MS: m / z = 311 [M+H] +

[0150] Step O. Purification of Compound A (Compound

[19] ) [ka] Under a nitrogen atmosphere, compound A 1-ethanol solvate

[18] (4.00 g, 11.2 mmol) and n-butanol (32 mL) were mixed and dissolved at 110 ° C. After cooling to 85 ° C., compound A crystals (4.0 mg) prepared according to this method were added and stirred at 85 ° C. for 2 hours, at 75 ° C. for 1 hour, and at room temperature for 16 hours. The precipitated solid was collected by filtration, and the obtained solid was washed with n-butanol (8.0 mL) and ethyl acetate (8.0 mL) in sequence. The obtained wet solid was dried under reduced pressure to obtain compound A

[19] (3.18 g, 10.2 mmol) in a yield of 91.3%. NMR and MS of compound A synthesized in the same manner were measured. 1H-NMR (DMSO-d6) δ: 11.59 (br s, 1H), 8.08 (s, 1H), 7.11 (dd, 1H, J = 3.5, 2.5 Hz), 6.58 (dd, 1H, J = 3.5, 1.8 Hz), 4.16 (t, 1H, J = 8.3 Hz), 4.09-3.93 (m, 3H), 3.84-3.73 (m, 1H), 3.71 (d, 1H, J = 19.0 Hz), 3.65 (d, 1H, J = 19.0 Hz), 3.58 (dd, 1H, J = 8.2, 5.9 Hz), 2.69-2.59 (m, 2H), 2.23-2.13 (m, 1H), 1.12 (d, 3H, J = 7.2 Hz). MS: m / z = 311 [M+H] +

[0151] Compound A, synthesized by the same method, was subjected to single crystal X-ray structure analysis. (1) Single crystal growth method 10 mg of compound A was placed in a 2.0 mL wide-mouthed LaPha Robovial (registered trademark) vial, and 0.5 mL of chloroform was added to close the cap, allowing compound A to completely dissolve. To slowly evaporate the solvent, a hole was made in the septum attached to the cap with a Terumo (registered trademark) syringe needle, and the vial was left to stand at room temperature. The obtained single crystal was used for structural analysis. (2) Measuring equipment Beamline: SPring-8 BL32B2 Detector: Rigaku R-AXIS V diffractometer (3)Measurement method The single crystal was irradiated with synchrotron radiation of 0.71068 Å and X-ray diffraction data was measured. (4)Analysis method The absolute configuration of Compound A was determined to be (3S,4R) by a method utilizing the anomalous X-ray scattering effect of the chlorine atom of the obtained chloroform solvate of Compound A. The stereostructures of each of the synthesis intermediates of Compound A were identified from the absolute configuration of Compound A.

[0152] Characterization of α-crystals X-ray Powder Diffraction (XRPD) The α-crystal was characterized by XRPD using a Spectris PANalytical instrument model: X'Pert Pro with the following data collection parameters: [Table 5]

[0153] The XRPD pattern of the α crystal is shown in FIG. 1, and the corresponding data is shown in Tables 1-8 below. [Table 6-1] [Table 6-2]

[0154] Differential Scanning Calorimetry (DSC) DSC data was collected on a TA Instruments model Q2000 instrument with the following parameters: Sample size: approx. 3 mg Pan: Aluminum sealed pan Range: 25~230℃ Heating rate: 2°C / min under nitrogen flow The DSC thermogram of the α crystal is shown in FIG. 4 and shows a single endothermic event with an onset at 185°C and a peak at 188°C.

[0155] Thermogravimetric differential thermal analysis (TG-DTA) TG-DTA data was collected on a Mettler Toledo model: TGA / SDTA851e / SF instrument with the following parameters: Sample: Approximately 5 mg Range: 25~250℃ Heating rate: 2°C / min under nitrogen flow The extrapolated onset temperature was 186.29° C., and no weight loss was observed in the range of 25 to 220° C. The TG-DTA data of the α crystal is shown in FIG.

[0156] solid 13 C NMR solid 13 C NMR data was collected on a Bruker BioSpin Corporation AVANCE III 400 instrument with the following parameters: Probe: 4 mm CP / MAS probe Measurement temperature: room temperature Standard: Glycine (external standard: downfield peak set at 176.03 ppm) Measurement nuclei: 13 C(100.6228303 MHz) Rotation speed: 14.3 kHz Pulse repetition time: 5 seconds Accumulation count: 3072 times Pulse mode: CP / MAS measurement Alpha crystal solid 13 C NMR data is shown in Figure 10 and has peaks at 14.8, 17.0, 24.5, 27.2, 35.0, 35.9, 38.6, 48.8, 49.5, 53.6, 78.3, 101.4, 103.0, 116.2, 118.0, 122.0, 122.7, 151.2, 154.8, 162.4 and 163.3 ppm.

[0157] Example 2 Preparation and characterization of compound A β crystals preparation Compound A (3992.3 g, α crystals) passed through a 500 μm sieve was crushed under the following conditions using a Spiral Jet Mill 100AS (manufactured by Hosokawa Micron Corporation) to obtain a crushed product (3473.6 g) together with compound A (361.0 g) adhering to the nozzle ring.

[0158] Grinding conditions Gas used: Nitrogen Grinding nozzle: diameter 1.5 mm x 4 Ejector nozzle: diameter 1.3 mm Grinding pressure: 0.50~0.60 MPa Ejector air pressure: 0.50~0.60 MPa Compound A feed rate: 8 g / min

[0159] Compound A (50.0 g, 161 mmol) attached to the nozzle ring was added to a mixed solution of 1-butanol / acetonitrile (1:3 v / v) (250 mL), and the mixture was stirred at 40°C for 10 days. The resulting suspension was cooled to room temperature and stirred at room temperature for an additional 24 hours. The precipitated crystalline material was collected by filtration. The resulting crystalline product was washed twice with ethyl acetate (50 mL) and dried under reduced pressure at 40°C to obtain β-crystals of compound A (35.5 g, yield 71%).

[0160] Characterization Powder X-ray diffraction The XRPD pattern of the β crystal is shown in Figure 2, and the corresponding data is shown in Table 2-1 below. The instrument and data collection parameters were as described in Example 1 above for characterizing the α crystal. [Table 7]

[0161] Differential Scanning Calorimetry (DSC) DSC data was collected on a TA Instruments model Q2000 instrument with the following parameters: Sample size: approx. 3 mg Pan: Aluminum sealed pan Range: 25~230℃ Heating rate: 2°C / min under nitrogen flow The DSC thermogram of the β-form is shown in FIG. 5 and shows a single endothermic event with an onset at 185°C and a peak at 187°C.

[0162] Thermogravimetric differential thermal analysis (TG-DTA) TG-DTA data was collected as described in Example 1 above, except that the measurement range for β crystals was 25-230° C. An endothermic peak was detected at 188.59° C. with an extrapolated onset temperature of 186.68° C., and no weight loss was observed in the range of 25-220° C. The data for β crystals is shown in FIG.

[0163] solid 13 C NMR solid 13 C NMR data was collected on the β crystal as described in Example 1 above. 13 The C NMR spectrum is shown in Figure 11 and has peaks at 16.5, 25.8, 26.5, 33.1, 34.8, 36.7, 38.8, 48.2, 53.4, 77.7, 79.5, 101.2, 102.6, 117.5, 120.6, 151.1, 154.3 and 166.1 ppm.

[0164] Example 3 Preparation and characterization of compound A gamma crystals Preparation Example 1 Compound A (2491.5 g, α crystals) passed through a 500 μm sieve was pulverized in a Spiral Jet Mill 100AS (manufactured by Hosokawa Micron Corporation) under the following conditions to obtain a pulverized material (2106.5 g) and compound A (247.9 g) adhering to the nozzle ring.

[0165] Grinding conditions Gas used: Nitrogen Grinding nozzle: diameter 1.5 mm x 4 Ejector nozzle: diameter 1.3 mm Grinding pressure: 0.50~0.60 MPa Ejector air pressure: 0.50~0.60 MPa Compound A feed rate: 4 g / min

[0166] Compound A (100 g, 322 mmol) attached to the nozzle ring was added to formamide (330 mL) under nitrogen, and seed crystals (1.00 g of gamma crystals, which may also contain some beta crystals of compound A) were added to the mixture. The mixture was stirred at room temperature for 30 days. The crystalline precipitate was collected by filtration and washed twice with ethyl acetate (150 mL). The resulting wet crystals were added to ethyl acetate (300 mL) under nitrogen, and the mixture was stirred at room temperature for 30 minutes. The crystalline precipitate was collected by filtration, washed twice with ethyl acetate (150 mL), and dried under reduced pressure at 40°C to obtain gamma crystals of compound A (74.1 g, 74% yield).

[0167] Preparation Example 2 Compound A α crystals (containing a small amount of unquantified β crystals) (100 mg, 0.322 mmol) were added to N,N-dimethylformamide (0.2 mL) and the mixture was stirred at room temperature for 6 days. The crystalline precipitate was collected by filtration. The resulting wet crystalline material was dried under reduced pressure at room temperature for 18 hours to give compound A γ crystals (13.7 mg, 13.7% yield).

[0168] Characterization Powder X-ray diffraction The XRPD pattern of the γ crystal is shown in Figure 3, and the corresponding data is shown in Table 3-1 below. The instrument and data collection parameters were as described in Example 1 above for characterizing the α crystal. [Table 8-1] [Table 8-2]

[0169] Differential Scanning Calorimetry (DSC) DSC data was collected on a TA Instruments model Q2000 instrument with the following parameters: Sample size: approx. 3 mg Pan: Aluminum sealed pan Range: 25~230℃ Heating rate: 2°C / min under nitrogen flow The DSC thermogram of the gamma crystal is shown in FIG. 6 and shows a single endothermic event with an onset and peak at 196°C.

[0170] Thermogravimetric differential thermal analysis (TG-DTA) TG-DTA data was collected as described above in Example 1. An endothermic peak was detected at 198.68° C. with an extrapolated onset temperature of 197.38° C., and no weight loss was observed in the range of 25-220° C. The data for the gamma crystal is shown in FIG.

[0171] solid 13 C NMR solid 13 C NMR data was collected on the gamma crystal as described in Example 1 above. 13 The C NMR spectrum is shown in Figure 12 and has peaks at 16.9, 26.5, 32.9, 36.4, 48.1, 53.7, 78.6, 102.6, 116.4, 117.9, 121.5, 151.8, 154.6 and 162.9 ppm.

[0172] Example 4 Quantitative determination of β and γ crystals in α crystal samples The presence of β and γ crystals was analyzed for a manufacturing batch of α crystals of Compound A and an ointment formulation containing α crystals of Compound A. Using the XRPD method, β and γ crystals were detected at a level of 1 w / w%. The batches of compound A α crystals used in this analysis are shown in Table 4-1. [Table 9]

[0173] The batches of ointment containing α crystals of Compound A (3%) used in this analysis are shown in Table 4-2. RH indicates relative humidity. M indicates period in months. [Table 10]

[0174] The amounts of β and γ crystals in the batches and ointments were quantified using a PANalytical X'Pert PRO powder X-ray diffractometer operated with the following parameters: [Table 11]

[0175] β Crystal Analysis Preparation of test samples (α-crystals of Compound A, drug substance) A portion of the Compound A test sample was ground to a fine powder in an agate mortar. Approximately 10 mg was placed on a sample holder.

[0176] Preparation of test samples (ointments) Approximately 1 g of the ointment test sample was suspended in 80 mL of n-hexane. The flask was stoppered and vigorously shaken for 30 seconds. The mixture was suction filtered using quantitative filter paper (5B) and washed five times with 5 mL of n-hexane. Approximately 10 mg of the precipitate was placed on a sample holder.

[0177] Preparation of standard samples Compound A, lot U (α crystal) was mixed with lot P-3273-58 (β crystal) to obtain final concentrations of 2, 5 and 10 w / w%, and mixed in a mortar. Approximately 10 mg was placed on a sample holder.

[0178] procedure According to the above instrument settings and data collection parameters, powder X-ray diffraction measurements were performed on the test samples and standard samples (see the 17th Revised Japanese Pharmacopoeia (April 1, 2016, English version, pages 79-83, Powder X-ray Diffraction Measurement Method, General Test Method, Method and Apparatus)). The peak areas of the diffraction peak (10.6°) obtained from the standard sample and the test sample were measured by automatic or manual integration. The amount (%) of β crystals in the test sample was calculated using a calibration curve created from the peak area of ​​the standard sample. The powder X-ray diffraction patterns obtained from standard samples containing 0%, 2%, 5% and 10% w / w of β crystals are shown in FIG.

[0179] Analysis of gamma crystals Preparation of test samples (α-crystals of Compound A, drug substance) A portion of the Compound A test sample was ground to a fine powder in an agate mortar. Approximately 10 mg was placed on a sample holder.

[0180] Preparation of test samples (ointments) Approximately 1 g of the ointment test sample was suspended in 80 mL of n-hexane. The flask was stoppered and vigorously shaken for 30 seconds. The mixture was suction filtered using quantitative filter paper (5B) and washed five times with 5 mL of n-hexane. Approximately 10 mg of the precipitate was placed on a sample holder.

[0181] Preparation of standard samples Compound A lot YKF56-28G (γ crystal) was added to lot U (α crystal) to obtain final concentrations of 1, 2 and 5 w / w%, and mixed in a mortar. Approximately 10 mg was placed on a sample holder.

[0182] procedure According to the above instrument settings and data collection parameters, powder X-ray diffraction measurements were performed on the test samples and standard samples (see the 17th Revised Japanese Pharmacopoeia (April 1, 2016, English version, pages 79-83, Powder X-ray Diffraction Measurement Method, General Test Methods, Methods and Apparatus)). The peak areas of the diffraction peaks (16.6°) obtained from the standard samples and test samples were measured by automatic or manual integration. If the peak area of ​​the test sample was less than or equal to that of the 1% standard sample, it was recorded as "less than or equal to 1%". If the peak area of ​​the test sample was greater than that of the 1% standard sample and less than or equal to that of the 2% standard sample, it was recorded as "less than or equal to 2%". If the peak area of ​​the test sample was greater than that of the 2% standard sample and less than or equal to that of the 5% standard sample, it was recorded as "less than or equal to 5%". The powder X-ray diffraction patterns obtained from standard samples containing 0%, 1%, 2% and 5% w / w γ crystals are shown in FIG.

[0183] result The quantitative results are summarized in Table 4-3. Compound A drug substance lot P, and JTE-052 ointment lot numbers 223-1A and 239-1A manufactured from drug substance lot P all contained measurable amounts of β crystals. [Table 12]

[0184] Example 5 Single crystal X-ray data Single crystal X-ray structures were obtained for the α, β and γ crystals according to the following parameters. The crystal structure data are shown in Table 5-1. Single crystal data for the α-form were obtained at the SPring-8 BL41XU beamline using a Rayonix MX225HE detector with an irradiation wavelength of 0.71068 Å. Single crystal data for the β and γ crystals were obtained using a DECTRIS PILATUS3 6M detector and the SPring-8 BL41XU beamline with an irradiation wavelength of 0.71068 Å. [Table 13]

[0185] Example 6 Competition experiment between α and β crystals of compound A The α crystal and the β crystal of compound A were mixed in a weight ratio of 1:1, and 1-butanol (800 μL) was added to this mixture (80 mg). This suspension was stirred at room temperature for 12 days. After filtration at the same temperature, it was dried under reduced pressure at room temperature for 19 hours. The diffraction angle 2θ and diffraction intensity were measured by powder X-ray diffraction for the α crystal of compound A used, the β crystal of compound A used, the 1:1 weight ratio mixture of α crystal and β crystal of compound A before stirring, and the obtained crystal. The apparatus and data collection parameters in this method are the same as those described in the characterization of the α crystal in Example 1 above. The obtained spectrum is shown in FIG. 15. The figure shows, from the bottom, the spectra of the α crystal of compound A used, the β crystal of compound A used, the 1:1 weight ratio mixture of α crystal and β crystal of compound A before stirring, and the crystal obtained after stirring. The diffraction intensity ratio of the α crystal peak at a diffraction angle 2θ of 10.2° and the β crystal peak at a diffraction angle 2θ of 10.6° was compared before and after stirring. As shown in the table below, the diffraction intensity ratio of the β crystal peak to the α crystal peak was higher after stirring compared to before stirring. [Table 14]

[0186] Example 7 Competition experiment between α and γ crystals of compound A The α crystal and the γ crystal of compound A were mixed in a weight ratio of 1:1, and 1-butanol (1 mL) was added to this mixture (100 mg). This suspension was stirred at room temperature for 11 days. It was filtered at the same temperature. The diffraction angle 2θ and diffraction intensity were measured by powder X-ray diffraction for the α crystal of compound A used, the γ crystal of compound A used, the 1:1 weight ratio mixture of α crystal and γ crystal of compound A before stirring, and the obtained crystal. The apparatus and data collection parameters in this method are the same as those described in the characterization of the α crystal in Example 1 above. The obtained spectrum is shown in FIG. 16. The figure shows, from the bottom, the spectra of the α crystal of compound A used, the γ crystal of compound A used, the 1:1 weight ratio mixture of α crystal and γ crystal of compound A before stirring, and the crystal obtained after stirring. The diffraction intensity ratio of the α crystal peak at a diffraction angle 2θ of 10.2° and the γ crystal peak at a diffraction angle 2θ of 10.7° was compared before and after stirring. As shown in the table below, the diffraction intensity ratio of the γ crystal peak to the α crystal peak was higher after stirring than before stirring. [Table 15]

[0187] Example 8 Competition experiment between β and γ crystals of compound A (1) The β crystal and the γ crystal of compound A were mixed in a weight ratio of 1:1, and formamide (1 mL) was added to this mixture (150 mg). The suspension was stirred at room temperature for 1 day. It was then filtered at the same temperature. (2) The β crystal and the γ crystal of compound A were mixed in a weight ratio of 1:1, and N,N-dimethylformamide (1 mL) was added to this mixture (150 mg). The suspension was stirred at room temperature for 1 day. It was then filtered at the same temperature. (3) Compound A β crystals and γ crystals were mixed in a weight ratio of 1:1, and dimethyl sulfoxide (1 mL) was added to this mixture (800 mg). The suspension was stirred at room temperature for 1 day. It was then filtered at the same temperature. The diffraction angle 2θ and diffraction intensity were measured by powder X-ray diffraction for the β crystal of compound A used, the γ crystal of compound A used, a 1:1 weight ratio mixture of β crystal and γ crystal of compound A before stirring, and the crystals obtained in (1), (2) and (3). The apparatus and data collection parameters in this method were the same as those described in the characterization of the α crystal in Example 1 above. The obtained spectra are shown in FIG. 17. The figure shows, from the bottom, the spectra of the γ crystal of compound A used, the β crystal of compound A used, a 1:1 weight ratio mixture of β crystal and γ crystal of compound A before stirring, the crystals obtained from formamide, those from N,N-dimethylformamide, and those from dimethyl sulfoxide. According to the results of (1), (2) and (3), the mixed crystals formed a single γ crystal.

[0188] Example 9 Solubility Test Each sample (i.e., α, β and γ crystals of Compound A) was weighed into a 4 mL glass vial. 3 mL of the test liquid was added to the vial to suspend the sample. Approximately 150 mg of the sample was weighed out for the test liquid of the Japanese Pharmacopoeia's solubility test No. 1, and approximately 15 mg was weighed out for the test liquid of the Japanese Pharmacopoeia's solubility test No. 2 and water. Each mixture was shaken for 3 hours in a thermostatic shaking bath (manufactured by Taitec Co., Ltd.) at 20°C. After shaking, the supernatant was filtered through a 0.2 μm pore size-4 mm diameter polytetrafluoroethylene disk filter (Millex-LG; manufactured by Millipore Co., Ltd.). Measurements were performed by high performance liquid chromatography (HPLC). The results are shown in the table below. [Table 16] The α-form showed the highest solubility in each of the solvents measured, while the γ-form showed the lowest solubility in each of the solvents measured.

[0189] Example 10 Formulation examples Examples of formulations containing compound A (e.g., α crystals, β crystals, γ crystals, or a mixture of any of the above) are shown below, but are not limited to these.

[0190] Formulation Example 1 (Capsule Production) 1)Compound A 30mg 2) Microcrystalline cellulose 10mg 3) Lactose 19mg 4) Magnesium stearate 1mg Components 1), 2), 3) and 4) are mixed and filled into a gelatin capsule.

[0191] Formulation Example 2 (Tablet Production) 1) Compound A 10g 2) Lactose 50g 3) 15g corn starch 4) Carmellose calcium 44g 5) Magnesium stearate 1g The total amount of components 1), 2), and 3) and 30 g of component 4) are mixed with water, vacuum dried, and then granulated. 14 g of component 4) and 1 g of component 5) are mixed with the granulated powder, and the mixture is compressed into tablets using a tablet press. In this way, 1000 tablets containing 10 mg of compound A per tablet are obtained.

[0192] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to be within the scope of the appended claims. All patents, patent applications, and journal articles cited in this application are hereby incorporated by reference in their entirety.

Claims

1. A crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, which is a β-form, has a powder X-ray diffraction pattern including a characteristic peak at about 11.8 in 2θ (°).

2. 2. The crystalline form of claim 1, having an X-ray powder diffraction pattern comprising two or more characteristic peaks selected from about 10.5, about 11.8, about 19.3 and about 22.0 in degrees 2θ.

3. 2. The crystalline form of claim 1, having a powder X-ray diffraction pattern comprising three or more characteristic peaks selected from about 7.8, about 10.5, about 11.8, about 13.4, about 13.9, about 17.8, about 19.3, about 22.0, about 23.6 and about 28.0 in degrees 2θ.

4. 4. The crystalline form of any one of claims 1 to 3, having a DSC thermogram characterized by an endothermic peak at about 186°C.

5. 5. The crystalline form of any one of claims 1 to 4, having a purity of at least about 50%.

6. 5. The crystalline form of any one of claims 1 to 4, having a purity of at least about 75%.

7. 5. The crystalline form of any one of claims 1 to 4, having a purity of at least about 85%.

8. 5. The crystalline form of any one of claims 1 to 4, having a purity of at least about 90%.

9. 5. The crystalline form of any one of claims 1 to 4, having a purity of at least about 95%.

10. A crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, which is a gamma crystal, has a powder X-ray diffraction pattern including a characteristic peak at about 16.5 in 2θ (°).

11. 11. The crystalline form of claim 10, having an X-ray powder diffraction pattern comprising two or more characteristic peaks selected from about 16.5, about 17.7, about 21.4, about 21.8 and about 23.1 in degrees 2θ.

12. 11. The crystalline form of claim 10, having an X-ray powder diffraction pattern comprising three or more characteristic peaks selected from about 7.7, about 10.6, about 13.3, about 13.9, about 15.5, about 16.5, about 17.7, about 17.9, about 19.0, about 21.4, about 21.8, about 23.1, about 23.7 and about 28.1 in degrees 2θ.

13. 13. The crystalline form of any of claims 10 to 12, having a DSC thermogram characterized by an endothermic peak at about 196°C.

14. 14. The crystalline form of any of claims 10 to 13, having a purity of at least about 50%.

15. 14. The crystalline form of any of claims 10 to 13, having a purity of at least about 75%.

16. 14. The crystalline form of any of claims 10 to 13, having a purity of at least about 85%.

17. 14. The crystalline form of any of claims 10 to 13, having a purity of at least about 90%.

18. 14. The crystalline form of any of claims 10 to 13, having a purity of at least about 95%.

19. A composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, comprising α-crystals and β-crystals.

20. 20. The composition of claim 19, consisting essentially of alpha and beta crystals.

21. 21. The composition of claim 19 or 20, wherein the β crystals are present in an amount of about 1 to about 50% w / w relative to the α crystals.

22. 21. The composition of claim 19 or 20, wherein the β crystals are present in an amount of about 1 to about 20% w / w relative to the α crystals.

23. The composition of claim 19 or 20, wherein the β crystals are present in an amount of about 1 to about 10% w / w relative to the α crystals.

24. The composition of claim 19 or 20, wherein the β crystals are present in an amount of about 1 to about 5% w / w relative to the α crystals.

25. The composition according to any one of claims 19 to 24, further comprising gamma crystals.

26. A composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile, comprising β crystals and γ crystals.

27. 27. The composition of claim 26, consisting essentially of β and γ crystals.

28. 28. The composition of claim 26 or 27, wherein the gamma crystals are present in an amount of about 1 to about 50% w / w relative to the beta crystals.

29. 28. The composition of claim 26 or 27, wherein the gamma crystals are present in an amount of about 1 to about 20% w / w relative to the beta crystals.

30. 28. The composition of claim 26 or 27, wherein the gamma crystals are present in an amount of about 1 to about 10% w / w relative to the beta crystals.

31. 28. The composition of claim 26 or 27, wherein the gamma crystals are present in an amount of about 1 to about 5% w / w relative to the beta crystals.

32. The composition according to any one of claims 26 to 31, further comprising alpha crystals.

33. 33. A pharmaceutical composition comprising the crystalline form or composition of any one of claims 1 to 32 and a pharma- ceutically acceptable carrier.

34. 34. The pharmaceutical composition of claim 33, further comprising a second therapeutic agent.